Latest News - GHealth News

Feb212025 by GHealth NewsNo Comments

World Health Day 2025: Prioritizing Maternal and Newborn Health for a Healthier Future

Latest News

GHealth News - The World Health Organization (WHO) has announced the theme for World Health Day 2025: "Healthy Beginnings, Hopeful Futures." This year’s campaign will focus on improving maternal and newborn health and survival. Observed annually on April 7—the anniversary of WHO’s founding in 1948—World Health Day highlights key global health issues. “This campaign comes at a critical time, aiming to help countries recover lost progress while showcasing new research and evidence to improve the health of women and newborns worldwide,” said Dr. Anshu Banerjee, WHO’s Director of Maternal, Newborn, Child and Adolescent Health and Ageing. “As humanitarian aid rollbacks threaten vital healthcare for millions, this is an opportunity to strengthen global support and collaboration—bringing ho...

Feb152025 by GHealth NewsNo Comments

Global Health at Risk: WHO Director-General Sounds Alarm on US Funding Cuts

Latest News

GHealth News - During a media briefing on Wednesday, WHO Director-General Tedros Adhanom Ghebreyesus discussed the impact of funding suspensions, pointing out disruptions to HIV treatment, delays in polio eradication, and limited resources for tackling mpox outbreaks in Africa. Tedros explained, "The suspension of funding to PEPFAR, the President’s Emergency Plan for AIDS Relief, resulted in an immediate halt to HIV treatment, testing, and prevention services across 50 countries." He emphasized that while life-saving services were granted a waiver, prevention programs for at-risk populations are still excluded, clinics have closed, and health workers have been furloughed. Tedros called on the US Government to rethink its funding strategy, at least until alternative solutions are f...

Feb62025 by GHealth NewsNo Comments

FDA Approves Journavx: A Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

Latest News

GHealth News - The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a groundbreaking 50mg oral tablet, as a first-in-class non-opioid analgesic for managing moderate to severe acute pain in adults. This new treatment works by targeting pain-signaling pathways in the peripheral nervous system, blocking pain signals before they reach the brain. Journavx is the first drug in this innovative class of pain management medications, offering an important alternative to opioid-based treatments. The FDA's approval is part of ongoing efforts to encourage the development of non-opioid pain treatments and reduce reliance on opioids. The efficacy of Journavx was established in two clinical trials, showing significant pain reduction in patients following abdominoplasty a...

Jan292025 by GHealth NewsNo Comments

China Rejects CIA Claim of COVID-19 Lab Leak

Latest News

GHealth News - China stated on Monday that a laboratory origin of COVID-19 was "extremely unlikely," following the CIA's assertion that the virus was more likely to have originated from a lab than through natural transmission. "The conclusion that a laboratory leak is extremely unlikely was reached by the China-WHO joint expert team based on field visits to relevant laboratories in Wuhan," said foreign ministry spokeswoman Mao Ning. "This conclusion has been widely recognized by both the international and scientific communities," she added. On Saturday, the CIA reported that the virus was "more likely" to have leaked from a Chinese lab rather than being transmitted through animals.